Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)
H Fensterer, Thomas M. Gress(Universitätsklinikum Gießen und Marburg), Peter Barth(Philipps University of Marburg), U. Settmacher, Patrick Michl(Heidelberg University), Hans‐Helge Müller, Cornelia Brendel(Philipps University of Marburg), Ralf‐Dieter Hofheinz(University of Mannheim), Carmen Schade‐Brittinger, Udo Lindig(Jena University Hospital), Esther Endlicher(University Hospital Regensburg), Detlef K. Bartsch(Philipps University of Marburg), Angela Märten(Boehringer Ingelheim (United States)), J. Faß, Wolfgang E. Schmidt(St. Josefs Hospital), Sandra Tebbe, M Ebert, Marko Kornmann(University Hospital Ulm)
Cited by 31
Related Papers
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863